• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Bulletin from the Annual General Meeting of Redsense Medical AB (publ) on May 20, 2026

REDSRegulatory press release2026-05-20 17:48
Download the release

Redsense Medical AB (publ) ("Redsense Medical" or the "Company") held its Annual General Meeting (the "AGM") on Wednesday May 20, 2026, in Halmstad, at which the following main resolutions were adopted. All resolutions were passed with the required majority. For detailed information regarding the content of the resolutions, please refer to the notice of the AGM and the complete proposals available on the Company's website, www.redsensemedical.com.

Appropriation of the result

The AGM resolved, in accordance with the Board of Directors' amended proposal, that the distributable funds shall be allocated so that SEK 32,043,031 shall be carried forward.

Discharge from liability for the members of the Board of Directors and the CEO

The AGM resolved to discharge the members of the Board of Directors and the CEO from liability for the financial year 2025.

The Board of Directors and the auditor

The AGM resolved, in accordance with the Nomination Committees' proposal, to re-elect Susanne Olauson, Johannes Köpple, Mike Griffiths and Martin Roos, and to elect Michael Kraus as Directors for the period until the end of the next AGM. Furthermore, the AGM re-elected Susanne Olauson as Chair of the Board for the period until the end of the next AGM.

More information about elected board members is available on the Company's website, www.redsensemedical.com.

The AGM resolved, in accordance with the Nomination Committees' proposal, to re-elect the registered audit Company Azets Revision och Rådgivning AB as auditor, with the authorized accountant Andreas Johansson as the auditor-in-charge.

As remuneration to the Board of Directors for the period until the next AGM, the AGM resolved, in accordance with the Nomination Committees' proposal, that remuneration shall be paid with SEK 250,000 to the Chairman of the Board and SEK 125,000 to each of the other Board members.

The AGM resolved, in accordance with the Nomination Committees' proposal, that remuneration to the auditor shall be paid in accordance with approved invoices.

Issue authorization

The AGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, on one or more occasions and with or without deviation from the shareholders' preferential rights, up to the next AGM, decide on issues of shares, warrants, and/or convertibles. By decision supported by the authorization, a maximum number of shares may be issued in the event of a new issue of shares, through the exercise of warrants and/or when converting convertibles, that corresponds to 20 percent of the total number of outstanding shares in the Company at the time when the authorization is exercised for the first time.